Danaher Corporation Acquires Abcam plc

Danaher Acquires Aldevron for $9.6 Billion

June 17, 2021

Biotechnology

Danaher Corporation entered into a definitive agreement to acquire Aldevron from EQT Private Equity for an enterprise value of approximately USD 9.6 billion. Aldevron, headquartered in Fargo, North Dakota with ~600 employees and additional operations in Madison, Wisconsin, will operate as a standalone company within Danaher's Life Sciences segment to expand Danaher's capabilities in genomic medicine and biologics manufacturing.

Danaher Corporation Acquires Genedata AG

August 19, 2024

Software

Danaher Corporation has acquired Genedata AG, a Basel-based provider of software solutions for biopharmaceutical R&D, and will integrate the company into its Life Sciences segment. The acquisition expands Danaher’s R&D workflow capabilities by adding Genedata’s data-driven informatics and automation tools to accelerate drug discovery and development.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

AbbVie to Acquire ImmunoGen for $10.1 Billion

November 30, 2023

Biotechnology

AbbVie has entered into a definitive agreement to acquire ImmunoGen for $31.26 per share in cash, valuing the company at approximately $10.1 billion. The deal gives AbbVie commercial rights to ELAHERE (mirvetuximab soravtansine-gynx) and ImmunoGen's ADC pipeline, expanding AbbVie's oncology capabilities; the transaction is expected to close in mid-2024 subject to shareholder and regulatory approvals.

BioAgilytix Acquires Cambridge Biomedical

November 4, 2019

Healthcare Services

BioAgilytix, a GHO Capital portfolio company, has acquired Cambridge Biomedical, a Cambridge, Massachusetts–based clinical research organisation specializing in large-molecule bioanalysis. The deal expands BioAgilytix's laboratory capacity and capabilities (including CLIA/CAP/GLP capabilities and PCR/molecular suites), broadens its geographic footprint into the Boston/Cambridge biotech cluster, and strengthens its cell- and gene-therapy bioanalytical offerings.

Merck Acquires Acceleron Pharma for $11.5 Billion

September 30, 2021

Biotechnology

Merck has entered into a definitive agreement to acquire Acceleron Pharma Inc. for $180 per share in cash, representing an approximate total equity value of $11.5 billion. The acquisition brings Acceleron's late-stage sotatercept program (for pulmonary arterial hypertension) and its REBLOZYL portfolio into Merck's cardiovascular pipeline, subject to tender offer completion and customary regulatory approvals.